UniQure’s cure for rare Lysosomal disease ready for phase III trial

22/09/2015 - 3 minutes

UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial targeting a rare Lysosomal disease. This has granted fast-track approval to launch its phase III trial for children with Sanfilippo Type B (MPS-III) in collaboration with France’s Institut Pasteur

uniqure-logo-retina-web-200x44UniQure is the Amsterdam gene-therapy biotech with a lot going on. Last year they secured a eye-watering €1.1M prescription deal for their drug Glybera (which treats the 150-200 individuals in the EU with the ultra-rare lipoprotein lipase deficiency). Now they’ve developed a clinical-phase Ib/II gene therapy for another rare genetic disorder, Sanfilippo disease type B.

Sanfilippo (also known as Mucopolysaccharidosis III) is an autosomal recessive disease group characterized by enzyme deficiencies, affecting around 1 in 70,000 births in the EU. There are 4 subtypes (A-D) and Sanfilippo B, in particular, is the subtype resulting from the N-acetyl-alpha-D-glucosaminidase (NaGLU) enzyme. NaGLU hydrolyses particular complex sugars responsible for the break down of heparin sulfate.

If allowed to accumulate, heparin sulfates severely affect multiple tissues (e.g.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member